Adaptive Biotechnologies (ADPT) EBIT (2018 - 2026)

Adaptive Biotechnologies has disclosed EBIT across 9 years of filings, most recently posting -$19.2 million for Q1 2026.

• EBIT for Q1 2026 came in at -$19.2 million, up 35.12% year-over-year; the trailing twelve-month figure through Mar 2026 was -$46.7 million (up 67.41% YoY), and the FY2025 annual result was -$57.1 million, up 64.86% from the prior year.
• EBIT came in at -$19.2 million for Q1 2026 at Adaptive Biotechnologies, down from -$12.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of $10.3 million in Q3 2025 to a low of -$71.1 million in Q4 2023.
• The 5-year median for EBIT is -$45.4 million (2022), against an average of -$39.2 million.
• Across the five-year window, EBIT plunged 81.36% in 2023 and soared 131.53% in 2025, its largest moves.
• Adaptive Biotechnologies' EBIT stood at -$39.2 million in 2022, then slumped by 81.36% to -$71.1 million in 2023, then surged by 52.39% to -$33.8 million in 2024, then surged by 62.25% to -$12.8 million in 2025, then tumbled by 50.36% to -$19.2 million in 2026.
• The last three EBIT figures came in at -$19.2 million (Q1 2026), -$12.8 million (Q4 2025), and $10.3 million (Q3 2025), per Business Quant data.